Featured Research

from universities, journals, and other organizations

Control of blood clotting by platelets described; provides medical promise

Date:
November 26, 2009
Source:
Virginia Tech
Summary:
Cell fragments called platelets are essential to promote blood clotting. Researchers have now discovered novel molecular interactions at the surface of platelets that control blood clotting.

Cell fragments called platelets are essential to promote blood clotting. Virginia Tech faculty members and students have discovered novel molecular interactions at the surface of platelets that control blood clotting.

The Virginia Tech researchers describe how platelets perform this life-saving magic in the November 24 online issue of the journal PLoS ONE (Public Library of Science) in the article "Sulfatides Partition Disabled-2 in Response to Platelet Activation," by Karen E. Drahos, biological sciences Master's degree student from Roanoke, Va.; John D. Welsh, a biological sciences undergraduate student from Pennington, N.J.; and biological sciences Assistant Professors Carla V. Finkielstein and Daniel G. S. Capelluto.

Capelluto and Finkielstein study how proteins signal from biological membranes. One such membrane protein is the integrin receptor that resides on the surface of platelets. A protein that strongly promotes platelet activation through the integrin receptor is thrombin. When there is tissue injury, thrombin converts fibrinogen into fibrin to form a network that traps red blood cells and platelets, creating a clot.

However, the platelets may not remain trapped. They can break their bonds with the network and thin or remove a clot -- a good thing if the clot is blocking an artery, as in thrombosis or stroke.

One part of the process is well known. When a platelet is stimulated, such as by thrombin, the protein Disabled-2 (Dab2) moves from where it is stored inside of the platelet to the surface, where it interacts with the integrin receptor. If this is the case, Dab2 inhibits blood clotting.

Experimentation and measurements by the Virginia Tech researchers revealed that Dab2 also binds to sulfatides, a lipid that also resides on the surface of platelets. Sulfatides sequester Dab2 proteins, preventing them from binding to the integrin receptor.

"That is, sulfatides partition Dab2 into two pools -- one pool that is part of the clotting process and one pool that prevents coagulation," said Capelluto.

When no longer on high alert to regulate clotting, the Dab2 proteins return to the interior of the platelet. "They are likely recycled for the next time they are needed," said Capelluto.

The study was Drahos' Master's thesis research, conducted in both Capelluto's and Finkielstein's labs. The thesis received the 2009 William Preston Society Thesis Award in Life Sciences for the best original research with potential to benefit all people. Co-author John Welsh is now a graduate student in Finkielstein's lab.

The PLoS ONE article stops with the definition of the chemistry of platelets' two responses to thrombin. But research by Finkielstein and Capelluto is looking at the platelet aggregation inhibitor process as a target for intervention to control bleeding and clotting. "This promises a high impact at the clinical level," said Capelluto. "The goal is a tool that could be used in surgery and could help people with bleeding or blood clotting disorders without drugs and side effects."


Story Source:

The above story is based on materials provided by Virginia Tech. Note: Materials may be edited for content and length.


Journal Reference:

  1. Drahos KE, Welsh JD, Finkielstein CV, Capelluto DGS. Sulfatides Partition Disabled-2 in Response to Platelet Activation. PLoS ONE, 2009; 4 (11): e8007 DOI: 10.1371/journal.pone.0008007

Cite This Page:

Virginia Tech. "Control of blood clotting by platelets described; provides medical promise." ScienceDaily. ScienceDaily, 26 November 2009. <www.sciencedaily.com/releases/2009/11/091123212551.htm>.
Virginia Tech. (2009, November 26). Control of blood clotting by platelets described; provides medical promise. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/11/091123212551.htm
Virginia Tech. "Control of blood clotting by platelets described; provides medical promise." ScienceDaily. www.sciencedaily.com/releases/2009/11/091123212551.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins